Supported by one trial
One controlled phase 3 trial met its main goal. Confirmed needs a second trial or regulatory approval for this use.
Daclizumab: reduce relapses and new lesions in relapsing MS
relapsing MS · T-cell co-stimulation / cytokine targeting
One controlled phase 3 trial met its main goal. It needs a second trial or regulatory approval to count as confirmed.
Daclizumab was withdrawn in the EU. A positive trial result does not mean the medicine is available.
- Trials
- 6
- Running now
- 0
- Controlled phase 2/3 trials
- 3
- People in controlled trials
- 3062
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 5
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Human genetics
Genes linked to MS that these medicines act on: IL2RA
Trials
Phase 3 · 2010 · Compared with interferon beta-1a · MSFT-NCT01064401
Other linked trials: 5
These linked trials do not set the status.
- SUSTAINStopped, other reason
Phase 3 · 2017 · Not randomised
- SELECTMet main goal
Phase 2 · 2008 · Placebo-controlled
- SELECTStopped, other reason
Phase 2 · 2006 · Placebo-controlled
- Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple SclerosisMet main goal
Phase 2 · 2005 · Not randomised
- Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisResult in a paper, not read yet
Phase 2 · 2003 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-11-02Status changed from Confirmed to Supported by one trial
- 2026-10-28Trials: 7 → 6
- 2026-10-27First listed as Confirmed
Related hypotheses
- Laquinimod: protect nerve tissue in relapsing MS
- Laquinimod: slow disability worsening in relapsing MS
- Abatacept: reduce relapses and new lesions in relapsing MS
- Daclizumab: reduce relapses and new lesions in relapsing and progressive MS
- Dapirolizumab pegol: reduce relapses and new lesions in relapsing MS
- Frexalimab: reduce relapses and new lesions in relapsing MS
- Laquinimod: reduce relapses and new lesions in relapsing MS
- Secukinumab: reduce relapses and new lesions in relapsing MS
- Ustekinumab: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error